Factors associated with serum hepatitis B surface antigen levels and its on-treatment changes in patients under lamivudine therapy

Antiviral Therapy

Volumn 17, Issue 1, 2012, Pages 71-79

  Chen, Jinjun ^a   Wang, Zhanhui ^a   Zhou, Bin ^a   Wang, Yanjun ^a   Hou, Jinlin ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BLOOD LEVEL; DISEASE ASSOCIATION; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; STATISTICAL ANALYSIS; TREATMENT DURATION; VIRUS INHIBITION; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; BIOMARKERS, PHARMACOLOGICAL; COHORT STUDIES; DNA, VIRAL; FEMALE; GENOTYPE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MULTIVARIATE ANALYSIS; SEX FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84862950164     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1925     Document Type: Article

References (29)

1. Brunetto MR. A new role for an old marker, HBsAg. J Hepatol 2010; 52:475-477.
2. Nguyen T, Thompson AJ, Bowden S, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 2010; 52:508-513.
3. Thompson AJ, Nguyen T, Iser D, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010; 51:1933-1944.
4. Chan HL, Wong VW, Wong GL, Tse CH, Chan HY, Sung JJ. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology 2010; 52:1232-1241.
5. Su TH, Hsu CS, Chen CL, et al. Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B. Antivir Ther 2010; 15:1133-1139.
6. Jaroszewicz J, Calle SB, Wursthorn K, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010; 52:514-522.
7. Chen J, Wang Z, Guo Y, et al. Serum HBsAg changes in HBeAg positive chronic hepatitis B patients with continuous viral load reductions during treatment with adefovir or peginterferon-alpha-2a. Antiviral Res 2009; 81:88-91.
8. Rijckborst V, Hansen BE, Cakaloglu Y, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010; 52:454-461.
9. Wursthorn K, Jung M, Riva A, et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 2010; 52:1611-1620.
10. Sun J, Wang Z, Ma S, et al. Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: a single center experience. J Med Virol 2005; 75:391-398. (Pubitemid 40175903)
11. Zeng G, Wang Z, Wen S, et al. Geographic distribution, virologic and clinical characteristics of hepatitis B virus genotypes in China. J Viral Hepat 2005; 12:609-617. (Pubitemid 41532492)
12. Chen JJ, Wang ZH, Ma SW, et al. [Changes of serum HBsAg in HBeAg positive chronic hepatitis patients with sustained viral response to long-term lamivudine treatment]. Zhonghua Gan Zang Bing Za Zhi 2008; 16:416-420. Chinese.
13. Wang J, Zhou B, Lai Q, et al. Clinical and virological characteristics of chronic hepatitis B with concurrent hepatitis B E antigen and antibody detection. J Viral Hepat 2011 18:646-652.
14. DeLoia JA, Burk RD, Gearhart JD. Developmental regulation of hepatitis B surface antigen expression in two lines of hepatitis B virus transgenic mice. J Virol 1989; 63:4069-4073. (Pubitemid 19205488)
15. Farza H, Salmon AM, Hadchouel M, et al. Hepatitis B surface antigen gene expression is regulated by sex steroids and glucocorticoids in transgenic mice. Proc Natl Acad Sci U S A 1987; 84:1187-1191. (Pubitemid 17027317)
16. Wang SH, Yeh SH, Lin WH, Wang HY, Chen DS, Chen PJ. Identification of androgen response elements in the enhancer I of hepatitis B virus: a mechanism for sex disparity in chronic hepatitis B. Hepatology 2009; 50:1392-1402.
17. Almog Y, Klein A, Adler R, Laub O, Tur-Kaspa R. Estrogen suppresses hepatitis B virus expression in male athymic mice transplanted with HBV transfected Hep G-2 cells. Antiviral Res 1992; 19:285-293.
18. Sugiyama M, Tanaka Y, Kato T, et al. Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. Hepatology 2006; 44:915-924. (Pubitemid 46489556)
19. Moucari R, Martinot-Peignoux M, Mackiewicz V, et al. Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a. Antivir Ther 2009; 14:1183-1188.
20. Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49:1141-1150.
21. Thibault V, Stitou H, Desire N, Valantin MA, Tubiana R, Katlama C. Six-year follow-up of hepatitis B surface antigen concentrations in tenofovir disoproxil fumarate treated HIVHBV-coinfected patients. Antivir Ther 2011; 16:199-205.
22. Zhou T, Guo H, Guo JT, Cuconati A, Mehta A, Block TM. Hepatitis B virus e antigen production is dependent upon covalently closed circular (ccc) DNA in HepAD38 cell cultures and may serve as a cccDNA surrogate in antiviral screening assays. Antiviral Res 2006; 72:116-124.
23. Tangkijvanich P, Komolmit P, Mahachai V, Sa-Nguanmoo P, Theamboonlers A, Poovorawan Y. Comparison between quantitative hepatitis B surface antigen, hepatitis B e-antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon-alpha-2b therapy in hepatitis B e-antigen-positive chronic hepatitis B. Hepatol Res 2010; 40:269-277.
24. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A 1996; 93:4398-4402. (Pubitemid 26144299)
25. Tsiang M, Rooney JF, Toole JJ, Gibbs CS. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 1999; 29:1863-1869. (Pubitemid 29247062)
26. Suh DJ, Um SH, Herrmann E, et al. Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B. Antimicrob Agents Chemother 2010; 54:1242-1247.
27. Wolters LM, Hansen BE, Niesters HG, DeHertogh D, de Man RA. Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. J Hepatol 2002; 37:137-144. (Pubitemid 34713065)
28. Manesis EK, Papatheodoridis GV, Tiniakos DG, et al. Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B. J Hepatol 2011; 55:61-68.
29. Brunetto MR, Oliveri F, Colombatto P, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010; 139:483-490.